Novartis expands biopharmaceutical plant in Slovenia
This article was originally published in Scrip
Sandoz, Novartis's generics arm, has opened a new $3.8 million, 430m2 production facility at the premises of Sandoz Slovenia (formerly Lek) in Menges, which will make modified proteins, including the epoetin alfa active ingredient. The site is one of Sandoz's three main biopharmaceutical development and production centres.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.